PARP inhibitors in prostate cancers, is it time for combinations?

Archive ouverte

Teyssonneau, Diego | Dariane, Charles | Barret, Eric | Beauval, Jean Baptiste | Brureau, Laurent | Fiard, Gaëlle | Fromont-Hankard, Gaëlle | Crehange, Gilles, Créhange | Gauthé, Mathieu | Ruffion, Alain | Renard-Penna, Raphaële | Mathieu, Romain | Sargos, Paul | Roupret, Morgan | Ploussard, Guillaume | Roubaud, Guilhem

Edité par CCSD ; SAGE Journals -

International audience. Despite several improvements in outcomes, metastatic prostate cancer remains deadly. Alterations in the homologous recombination repair (HRR) pathway are associated with more aggressive disease. Olaparib and rucaparib, two poly-ADP-ribose polymerase (PARP) inhibitors, have received approval from the authorities of several countries for their anti-tumoral effects in patients with metastatic castration-resistant prostate cancers harboring HRR gene alterations, in particular BRCA2. More recently, it has been hypothesized that new hormonal therapies (NHTs) and PARP inhibitors (PARPi) could have synergistic actions and act independently of HRR deficiency. This review proposes to discuss the advantages and disadvantages of PARPi used as monotherapy or in combination with NHTs and whether there is a need for molecular selection.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion